94 results
6-K
EX-99.1
GLPG
Galapagos NV
10 Feb 21
Current report (foreign)
11:31am
statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors … -Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
6-K
EX-99.1
GLPG
Galapagos NV
3 Nov 20
Current report (foreign)
6:00am
.
Gilead Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act … the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause
6-K
EX-99.1
GLPG
Galapagos NV
24 Jul 20
Current report (foreign)
9:45am
within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including … includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks
6-K
EX-99.1
GLPG
Galapagos NV
28 Sep 20
Current report (foreign)
6:00am
release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks … release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject
6-K
EX-99.1
GLPG
Galapagos NV
13 Oct 20
Current report (foreign)
6:15am
Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act … of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual
6-K
EX-99.1
k4em1z10on3 e5m5o
25 Mar 21
Galapagos appoints Bart Filius as President and Chief Operating Officer
6:00am
6-K
EX-99.1
398za1fl
6 Jan 21
Galapagos to present at 39th Annual J.P. Morgan Healthcare Conference
9:57am
6-K
EX-99.1
i0khcur9
15 Dec 20
Current report (foreign)
4:55pm
6-K
EX-99.2
oqoy cxigk4vbug6gxz6
29 Aug 19
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
4:44pm
6-K
EX-99.1
7xk9sdfs0t06fat
25 Sep 20
Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis
6:05am
6-K
EX-99.1
wsvasnd hy77ysaa1
2 May 23
Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer
4:49pm
6-K
EX-99.1
1cnpux4s2lotx 3bad
10 Nov 20
Current report (foreign)
6:05am
6-K
EX-99.1
a1o6zm4r5vqs1usb8k
15 Jun 23
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
5:03pm
6-K
EX-99.1
ypwmfzs59 crb18cs3
31 Aug 21
Galapagos announces planned retirement of CEO
3:46pm
6-K
EX-99.1
htkggtyjy
23 Dec 22
Galapagos announces changes to Executive Committee
6:05am
6-K
EX-99.1
pji7vv9ijrgjv dzq
26 Aug 20
Galapagos to present new insights in IPF and related clinical developments at the European Respiratory Society Congress
6:37am
6-K
EX-99.1
pejc uzjyxh
5 Jan 21
Selvita completes acquisition of Fidelta from Galapagos
7:00am
6-K
EX-99.1
p9lo6tosp u7wdfs
4 Jan 24
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4:07pm
6-K
EX-99.1
1f6 1fv8y
4 Jan 24
Current report (foreign)
5:32pm
6-K
EX-99.1
7yp5vc p640
3 Dec 20
Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
4:34pm